Melatonin
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Melatonin: From Circadian Rhythm Regulation to Migraine with Brainstem Aura
One-Sentence Summary
Melatonin is an endogenous pineal hormone best known for regulating circadian rhythm and the sleep-wake cycle; it currently has no registered indication in Australia (0 ARTG entries, market status: Not Marketed). The TxGNN model predicts a possible role in Migraine with Brainstem Aura, with an 87.90% prediction score, but this specific subtype currently has no dedicated clinical trials and only indirect support from 19 publications (mostly reviews and observational studies on migraine and sleep/melatonin physiology generally).
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not registered in Australia (0 ARTG entries); no approved indication is on file for this molecule |
| Predicted New Indication | Migraine with Brainstem Aura |
| TxGNN Prediction Score | 87.90% |
| Evidence Level | L4 |
| Australia Market Status | Not Marketed |
| Number of ARTG Entries | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available for melatonin in this evidence pack. Based on known pharmacology, melatonin is the principal hormone secreted by the pineal gland, synchronising circadian and sleep-wake rhythms via MT1/MT2 receptor signalling, and it has documented anti-inflammatory and antioxidant activity.
The mechanistic rationale specific to this prediction, per the repurposing analysis, is that melatonin secretion abnormalities and serotonergic pathway disturbances are shared features of migraine generally, but there is no evidence specific to the “migraine with brainstem aura” subtype. This subtype is clinically notable because triptans are contraindicated due to vasoconstriction risk — if melatonin lacks vasoconstrictive activity, it could theoretically be a safer prophylactic option for this population, but this requires subtype-specific research to confirm.
It is worth noting that a closely related, broader diagnosis in the same prediction set — migraine disorder (unspecified aura status) — has substantially stronger evidence: an evidence level of L1, including a completed Phase 3 RCT (NCT01357031, melatonin 3 mg vs amitriptyline vs placebo, n=192) and a published meta-analysis (PMID 36445912). This suggests melatonin’s general migraine-prophylaxis signal is comparatively mature, even though the aura-with-brainstem-symptoms subtype itself remains an open research question.
Clinical Trial Evidence
Currently no related clinical trials registered for Migraine with Brainstem Aura specifically.
(For context, general migraine prophylaxis with melatonin has been tested in a completed Phase 3 RCT — see the “Why is This Prediction Reasonable?” section above.)
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 27165014 | 2016 | RCT | J Neurol Neurosurg Psychiatry | Melatonin 3 mg vs amitriptyline 25 mg vs placebo for migraine prevention; melatonin was effective and better tolerated than amitriptyline. |
| 18810607 | 2008 | RCT (open-label) | Neurol Sci | 3-month open-label trial of melatonin 3 mg in 22 children with migraine/tension-type headache; most reported improvement. |
| 24909684 | 2015 | Cohort | Curr Drug Saf | Investigated safety and efficacy of melatonin for paediatric migraine prophylaxis. |
| 7641249 | 1995 | Cohort | Cephalalgia | Nocturnal melatonin excretion significantly lower in women with menstrually-associated migraine without aura vs controls. |
| 7954740 | 1994 | Cohort | Cephalalgia | Urinary melatonin excretion decreased throughout the ovarian cycle in menstrual migraine patients, further reduced during headache episodes. |
| 31054199 | 2019 | Cohort (negative result) | Headache | Evening urinary melatonin metabolite did not reliably predict next-day migraine in children/adolescents. |
| 9595871 | 1998 | Case series | Headache | Headache (including migraine) resolved within 2 weeks of melatonin 5 mg treatment in patients with delayed sleep phase syndrome. |
| 30906963 | 2019 | Review | Neurol Sci | Reviews the bidirectional relationship between sleep disorders and migraine/headache, including melatonin’s role. |
| 24437268 | 2013 | Review | Nihon Rinsho | Reviews circadian rhythm’s role in primary headache disorders including migraine with aura. |
| 28194570 | 2017 | Review | J Headache Pain | Reviews genetic/biochemical serotonergic system changes in migraine pathobiology, relevant to melatonin’s shared serotonin pathway. |
Australia Market Information
Melatonin currently has no ARTG entries (0 licenses on file); it is not marketed under this evidence pack’s data. No product listings are available to summarise.
Safety Considerations
Product information (PI) warnings, contraindications, and drug interaction data are not currently available for melatonin in this evidence pack — the drug is not registered on the ARTG, and the DDI query returned no results. This is flagged as a blocking gap for safety assessment: it prevents this candidate from entering an initial safety screen. Before considering this repurposing pathway further, TGA-approved Product Information (or equivalent overseas labelling) should be sourced and reviewed.
Conclusion and Next Steps
Decision: Hold
Rationale: Evidence specific to melatonin in migraine with brainstem aura is indirect (L4) — no dedicated clinical trials exist, and the literature draws mainly from general migraine, menstrual migraine, and sleep-disorder studies rather than this aura subtype. Combined with a blocking safety data gap (no warnings or contraindications available), the candidate cannot yet progress past initial screening.
To proceed, the following is needed:
- TFDA/TGA product warnings and contraindications (resolves blocking data gap)
- Detailed mechanism of action data, including confirmation of melatonin’s vascular (non-vasoconstrictive) profile relevant to the triptan-contraindicated subgroup
- Subtype-specific trial or subgroup data for migraine with brainstem aura (current evidence is extrapolated from general migraine populations)
- Given the stronger L1 evidence base for general migraine prophylaxis (Phase 3 RCT NCT01357031, meta-analysis PMID 36445912), consider evaluating melatonin for unspecified migraine disorder as a more evidence-mature parallel pathway
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.